• 1
    Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107:88591 (Epub Oct 11).
  • 2
    Byrd JC, Rai K, Peterson BL et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005;105:4953.
  • 3
    Ribera JM, Vinolas N, Urbano-Ispizua A, Gallart T, Montserrat E, Rozman C. “Spontaneous” complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature. Blood cells 1987;12:47183.
  • 4
    Ziegler-Heitbrock HW, Schlag R, Flieger D, Thiel E. Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood 1989;73:142630.
  • 5
    Marks DI, Lush R, Cavenagh J et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002;100:310814.
  • 6
    Dreger P, Brand R, Milligan D et al. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia 2005;19:102933.
  • 7
    Gribben JG, Zahrieh D, Stephans K et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005;106:438996.
  • 8
    Kollgaard T, Petersen SL, Hadrup SR et al. Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation. Leukemia 2005;19:227380.
  • 9
    Rezvany MR, Jeddi-Tehrani M, Rabbani H et al. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. Br J Haematol 2000;111:60817.
  • 10
    Kokhaei P, Palma M, Hansson L, Osterborg A, Mellstedt H, Choudhury A. Telomerase (hTERT 611–626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. Exp Hematol 2007;35:297304.
  • 11
    Rezvany MR, Jeddi-Tehrani M, Rabbani H et al. Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. Br J Haematol 2000;111:2308.
  • 12
    Giannopoulos K, Hus I, Li L et al. The receptor for hyaluronic acid mediated motility (RHAMM/CD168) is a potential target for immunotherapy of patients with B-cell chronic lymphocytic leukemia. Blood 2005;106:93845.
  • 13
    Schmidt SM, Schag K, Muller MR et al. Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res 2004;64:116470.
  • 14
    Siegel S, Wagner A, Kabelitz D et al. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies. Blood 2003;102:441623.
  • 15
    Giannopoulos K, Schmitt M. Targets and strategies for T-cell based vaccines in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 2006;47:202836.
  • 16
    Banchereau J, Palucka AK, Dhodapkar M et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:64518.
  • 17
    Kokhaei P, Choudhury A, Mahdian R et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004;18:18105.
  • 18
    Kokhaei P, Rezvany MR, Virving L et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 2003;17:8949.
  • 19
    Jarnjak-Jankovic S, Pettersen RD, Saeboe-Larssen S, Wesenberg F, Gaudernack G. Evaluation of dendritic cells loaded with apoptotic cancer cells or expressing tumour mRNA as potential cancer vaccines against leukemia. BMC cancer 2005;5:20.
  • 20
    Palma M, Adamson L, Hansson L et al. Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia. Cancer Immunol Immunother 2008;57:170510.
  • 21
    Svensson A, Adamson L, Pisa P, Petersson M, Hansson M. Monocyte enriched apheresis for preparation of dendritic cells (DC) to be used in cellular therapy. Transfus Apher Sci 2005;33:16573.
  • 22
    Hus I, Rolinski J, Tabarkiewicz J et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005;19:16217.
  • 23
    Hus I, Schmitt M, Tabarkiewicz J et al. Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response. Leukemia 2008;22:100717.
  • 24
    Pretlow TG II, Pretlow TP. Centrifugal elutriation (counterstreaming centrifugation) of cells. Cell Biophys 1979;1:195210.
  • 25
    Berger TG, Strasser E, Smith R et al. Efficient elutriation of monocytes within a closed system (Elutra) for clinical-scale generation of dendritic cells. J Immunol Methods 2005;298:6172.
  • 26
    Adamson L, Palmborg A, Svensson A et al. Development of a technology platform for large-scale clinical grade production of DC. Cytotherapy 2004;6:36371.
  • 27
    Kokhaei P, Adamson L, Palma M et al. Generation of DC-based vaccine for therapy of B-CLL patients. Comparison of two methods for enriching monocytic precursors. Cytotherapy 2006;8:31826.
  • 28
    Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004;10:47580.